Defiance Daily Target 2X Short LLY ETF

Tian Ruixiang

ENvue Medical

LINKERS INDUSTRIES LIMITED

Smart Logistics Global

Lottery.com

Namib Minerals

Bio-Key

PicoCELA

Murano Global BV

Propanc Biopharma

ELIL

LLYZ

LLYX

ELIS

Big pharma faces new pricing pressures as Medicare adds 15 well-known drugs to its negotiation list, including Pfizer's Xeljanz and Novartis' Cosentyx. These drugs, used by 1.8 million Medicare beneficiaries, account for $27 billion in spending. While negotiated prices won't take effect until 2028, the move signals long-term pricing pressure on established drugs, impacting revenue for major companies like Pfizer, Novartis, and Eli Lilly.

- The Centers for Medicare & Medicaid Services has included 15 well-known drugs from Pfizer, Novartis, and Eli Lilly in its latest round of Medicare price negotiations.  
- These drugs, widely used by Medicare beneficiaries and driving significant prescription spending, signal a focused effort by Medicare to apply pricing pressure on established pharmaceutical products.  
- While negotiated prices will not take effect until 2028, the move indicates a long-term challenge for big pharma regarding the pricing of their major drugs.

GuruFocus

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Pfizer

iShares US Pharma

Direxion Daily LLY Bear 1X Shares

NOVARTIS AG

Eli Lilly

Some of Pharma's Biggest Brands Face a New Reality
        (Status: Pending)

More than 4,400 lawsuits have been filed against manufacturers of GLP-1 weight-loss drugs like Ozempic and Wegovy, alleging serious side effects such as gastroparesis and sudden blindness. Plaintiffs claim the companies failed to adequately warn users of these risks. The lawsuits have emerged as the use of these drugs has surged among Americans seeking to manage obesity and related health issues. Drugmakers Novo Nordisk and Eli Lilly deny the allegations, asserting that the safety of their products is well-established and reflected in FDA-approved labeling.

Yahoo Finance

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Defiance Daily Target 2X Long NVO ETF

ALPS Medical Breakthrough

Novo Nordisk AS

iShares Biotechnology ETF

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

VG Health

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Weight-loss drugs draw thousands of lawsuits alleging serious harm

Eli Lilly & Co. (LLY) shares fell 2.19% to $1,039.51 on Tuesday, marking the third consecutive day of losses. The stock is currently 8.33% below its 52-week high of $1,133.95. In contrast, competitors like Johnson & Johnson, Pfizer, and AbbVie saw gains. The trading volume was 2.6 million, below the 50-day average of 3.2 million. The overall market showed mixed results, with the S&P 500 up 0.41% and the Dow down 0.83%.

Dow Jones

Johnson & Johnson

Eli Lilly & Co. Stock Underperforms Tuesday When Compared To Competitors

Eli Lilly and Co Inc. (NYSE:LLY) shares are currently trading at $1060.01, down 0.40%. The stock has decreased by 1.76% over the past month but increased by 31.78% over the past year. Investors are advised to consider the company's price-to-earnings (P/E) ratio, which is lower than the industry average of 127.31. A lower P/E may indicate undervaluation, but it could also suggest weak growth prospects. Investors should use the P/E ratio alongside other financial metrics and qualitative factors for informed decision-making.

benzinga_article

Ark Genomic Revolution ETF

Direxion S&P Biotech Bear 3X

A Look Into Eli Lilly and Co Inc's Price Over Earnings

Truist Securities Adjusts Eli Lilly Estimates Ahead of Q4 2025 Results

marketscreener

iShares Global Healthcare

Truist Securities Adjusts Eli Lilly Estimates Ahead of Q4 2025 Results

Eli Lilly (LLY) has received FDA Breakthrough Therapy designation for its candidate sofetabart mipitecan in treating platinum-resistant ovarian cancer, shifting focus back to oncology. The stock has shown volatility with a 1-day return of 2.12% and a 30-day return of 1.25%, but a strong 90-day return of 28.78% and a 1-year return of 36.52%. Currently trading at $1,064.29, it is about 4% below the average analyst price target of $1,189.18, suggesting it may be undervalued. Analysts project significant growth in sales for its tirzepatide franchise, raising questions about future pricing and valuation risks.

Simplywall

Eli Lilly (LLY) Valuation Check After Breakthrough Therapy Status For Sofetabart Mipitecan

The company got some bad news to start 2026.

Should you dump Eli Lilly's shares after this setback?

Resona Asset Management Co. Ltd. has reduced its stake in Eli Lilly and Company (NYSE: LLY) by 5.5%, selling 15,289 shares in the third quarter. The firm now holds 263,865 shares, valued at approximately $199.7 million, making it the 14th largest position in its portfolio. Eli Lilly's stock has seen a recent decline of 2.1%, with a current price of $1,065.05. The company reported strong earnings, beating estimates with $7.02 EPS and a revenue of $17.6 billion for the quarter, reflecting a 53.9% year-over-year increase. Additionally, Eli Lilly announced a quarterly dividend increase to $1.73 per share, payable on March 10th.

Market Beat

Resona Asset Management Co. Ltd. Sells 15,289 Shares of Eli Lilly and Company $LLY

Novo Nordisk's stock rose nearly 5% to $63.50 following strong demand for its oral Wegovy weight-loss pill, which recorded over 18,000 prescriptions in its first week. This performance surpassed Eli Lilly's Zepbound, which had 8,000 prescriptions in its second week. Goldman Sachs issued a Buy rating, citing potential earnings growth. Despite a 24.30% year-to-date gain, the stock is down 18.80% over the past year. Analysts remain mixed on price targets, and upcoming patent cliffs pose challenges. The next earnings report on February 4, 2026, will be crucial for future guidance.

Talkmarkets

SPDR S&P Health Equip

iShares US Medical Devices

Why Is Novo Nordisk Stock Up Today? Wegovy Pill Demand Looks Strong

Strive Compounding Pharmacy has filed a lawsuit against Eli Lilly and Novo Nordisk, alleging that the companies are suppressing competition in the GLP-1RA market to limit patient access to compounded medications. The lawsuit claims that Lilly and Novo are using their market dominance to undermine compounding pharmacies through exclusive partnerships and their own online pharmacies. Both companies have denied the allegations, asserting that Strive's claims are without merit and that they are committed to patient safety. The case highlights ongoing tensions between the pharmaceutical industry and compounding pharmacies.

Pharmaceutical Technology

Compounder sues Lilly and Novo for suppressing GLP-1RA competition

Defiance Daily Target 2X Short LLY ETF(LLYZ.US)

Some of Pharma's Biggest Brands Face a New Reality (Status: Pending)

Weight-loss drugs draw thousands of lawsuits alleging serious harm

Eli Lilly & Co. Stock Underperforms Tuesday When Compared To Competitors

A Look Into Eli Lilly and Co Inc's Price Over Earnings

Truist Securities Adjusts Eli Lilly Estimates Ahead of Q4 2025 Results